{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2",
      "carrageenan types",
      "coronavirus",
      "iota-carrageenan",
      "kappa-carrageenan",
      "lambda-carrageenan",
      "pseudotyping",
      "sulfated polymer",
      "variants of concern",
      "virus variants"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34947999",
  "DateCompleted": {
    "Year": "2022",
    "Month": "01",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "12",
        "Day": "08"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "13202",
      "10.3390/ijms222413202"
    ],
    "Journal": {
      "ISSN": "1422-0067",
      "JournalIssue": {
        "Volume": "22",
        "Issue": "24",
        "PubDate": {
          "Year": "2021",
          "Month": "Dec",
          "Day": "08"
        }
      },
      "Title": "International journal of molecular sciences",
      "ISOAbbreviation": "Int J Mol Sci"
    },
    "ArticleTitle": "Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.",
    "Abstract": {
      "AbstractText": [
        "The COVID-19 pandemic continues to spread around the world and remains a major public health threat. Vaccine inefficiency, vaccination breakthroughs and lack of supply, especially in developing countries, as well as the fact that a non-negligible part of the population either refuse vaccination or cannot be vaccinated due to age, pre-existing illness or non-response to existing vaccines intensify this issue. This might also contribute to the emergence of new variants, being more efficiently transmitted, more virulent and more capable of escaping naturally acquired and vaccine-induced immunity. Hence, the need of effective and viable prevention options to reduce viral transmission is of outmost importance. In this study, we investigated the antiviral effect of iota-, lambda- and kappa-carrageenan, sulfated polysaccharides extracted from red seaweed, on SARS-CoV-2 Wuhan type and the spreading variants of concern (VOCs) Alpha, Beta, Gamma and Delta. Carrageenans as part of broadly used nasal and mouth sprays as well as lozenges have the potential of first line defense to inhibit the infection and transmission of SARS-CoV-2. Here, we demonstrate by using a SARS-CoV-2 spike pseudotyped lentivirus particles (SSPL) system and patient-isolated SARS-CoV-2 VOCs to infect transgenic A549ACE2/TMPRSS2 and Calu-3 human lung cells that all three carrageenan types exert antiviral activity. Iota-carrageenan exhibits antiviral activity with comparable IC<sub>50</sub> values against the SARS-CoV-2 Wuhan type and the VOCs. Altogether, these results indicate that iota-carrageenan might be effective for prophylaxis and treatment of SARS-CoV-2 infections independent of the present and potentially future variants."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Virology, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany."
          }
        ],
        "LastName": "Fr\u00f6ba",
        "ForeName": "Maria",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Virology, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany."
          }
        ],
        "LastName": "Gro\u00dfe",
        "ForeName": "Maximilian",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Virology, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany."
          }
        ],
        "LastName": "Setz",
        "ForeName": "Christian",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Virology, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany."
          }
        ],
        "LastName": "Rauch",
        "ForeName": "Pia",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Virology, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany."
          }
        ],
        "LastName": "Auth",
        "ForeName": "Janina",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Virology, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany."
          }
        ],
        "LastName": "Spanaus",
        "ForeName": "Lucas",
        "Initials": "L"
      },
      {
        "Identifier": [
          "0000-0001-7316-7141"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany."
          }
        ],
        "LastName": "M\u00fcnch",
        "ForeName": "Jan",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany."
          }
        ],
        "LastName": "Ruetalo",
        "ForeName": "Natalia",
        "Initials": "N"
      },
      {
        "Identifier": [
          "0000-0001-8989-5813"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany."
          }
        ],
        "LastName": "Schindler",
        "ForeName": "Michael",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Marinomed Biotech AG, A-2100 Korneuburg, Austria."
          }
        ],
        "LastName": "Morokutti-Kurz",
        "ForeName": "Martina",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Marinomed Biotech AG, A-2100 Korneuburg, Austria."
          }
        ],
        "LastName": "Graf",
        "ForeName": "Philipp",
        "Initials": "P"
      },
      {
        "Identifier": [
          "0000-0003-0118-4297"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Marinomed Biotech AG, A-2100 Korneuburg, Austria."
          }
        ],
        "LastName": "Prieschl-Grassauer",
        "ForeName": "Eva",
        "Initials": "E"
      },
      {
        "Identifier": [
          "0000-0003-3715-2545"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Marinomed Biotech AG, A-2100 Korneuburg, Austria."
          }
        ],
        "LastName": "Grassauer",
        "ForeName": "Andreas",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institute of Virology, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany."
          }
        ],
        "LastName": "Schubert",
        "ForeName": "Ulrich",
        "Initials": "U"
      }
    ],
    "GrantList": [
      {
        "GrantID": "401821119/GRK2504",
        "Agency": "Deutsche Forschungsgemeinschaft",
        "Country": ""
      },
      {
        "GrantID": "MD-Thesis Scholarship Programme",
        "Agency": "Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg",
        "Country": ""
      },
      {
        "GrantID": "880687",
        "Agency": "Austrian Research Promotion Agency",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Int J Mol Sci",
    "NlmUniqueID": "101092791",
    "ISSNLinking": "1422-0067"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Polysaccharides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "9000-07-1",
      "NameOfSubstance": "Carrageenan"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "epidemiology",
        "immunology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Carrageenan"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chlorocebus aethiops"
    },
    {
      "QualifierName": [],
      "DescriptorName": "HEK293 Cells"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Polysaccharides"
    },
    {
      "QualifierName": [
        "drug effects",
        "metabolism",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Vaccination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vero Cells"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Replication"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors have read the journal\u2019s policy and declare that the authors Andreas Grassauer, Eva Prieschl-Grassauer, Philipp Graf, and Martina Morokutti-Kurz are employed by Marinomed Biotech AG. Andreas Grassauer and Eva Prieschl-Grassauer are co-founders of Marinomed Biotech AG. Andreas Grassauer, Eva Prieschl-Grassauer and Martina Morokutti-Kurz are inventors of a patent submission related to the content of the manuscript; the number of this patent application is EP20186334. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."
}